Comparative studies of epidermal growth factor, epidermal growth factor receptor, K-ras, and P53 in gallbladder carcinomas with and without an anomalous junction of pancreticobiliary duct

Hanada, Keiji; Itoh, Masaki; Fujii, Kenichi; Tsuchida, Akira; Ishimaru, Shouhei; Hirata, Manabu; Iwao, Toshiyasu; Kajiyama, Goro

doi:10.1016/0016-5085(95)24326-7

Search citation statements

Order By: Relevance

Paper Sections

Select...

U0126 and Gallbladder Cancer1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Activation of KRAS can induce the constitutive activation of the MAPK pathway and PI3K-AKT pathway, which rapidly develops the growth of the gallbladder epithelium (Leevers and Marshall, 1992;Thomas et al, 1992;Rubio et al, 1997). Furthermore, point mutation of P53 is also related to gallbladder cancer carcinogenesis (Hanada et al, 1997;Watanabe et al, 1999). Therefore, U0126 as a MAPK inhibitor has the potential to inhibit gallbladder cancer proliferation.…”

Section: U0126 and Gallbladder Cancermentioning

confidence: 99%

U0126: Not only a MAPK kinase inhibitor

et al. 2022

View full text Add to dashboard Cite

U0126, as an inhibitor of the MAPK signaling pathway, is closely related to various biological processes, such as differentiation, cell growth, autophagy, apoptosis, and stress responses. It makes U0126 play an essential role in balancing cellular homeostasis. Although U0126 has been suggested to inhibit various cancers, its complete mechanisms have not been clarified in cancers. This review summarized the most recent and relevant research on the many applications of U0126 and described its role and mechanisms in different cancer cell types. Moreover, some acknowledged functions of U0126 researched in the laboratory were listed in our review. We discussed the probability of using U0126 to restain cancers or suppress the MAPK pathway as a novel way of cancer treatment.

show abstract

Section: U0126 and Gallbladder Cancermentioning

confidence: 99%